News

  1. Ocular Therapeutix™ Announces Initiation Of Its First Pivotal Clinical Trial of OTX-TKI In Wet AMD 10/11/2023

    Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD). OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

  2. Enable Injections Receives First U.S. Food And Drug Administration (FDA) Approval 10/2/2023

    Enable Injections, Inc. (“Enable”) today announced that the U.S. Food and Drug Administration (FDA) has approved the  EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients’ daily lives.

  3. Sharps Technology Signs Asset Purchase Agreement To Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility And A 10-Year Purchase Agreement For Over $400 Million From Nephron Pharmaceuticals 9/27/2023

    Sharps Technology, Inc., an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033.

  4. CPHI Barcelona Announces Pharma Award Finalists 9/15/2023

    The shortlist was whittled down from more than 180 entries across 12 categories. Innovations cover the full pharmaceutical supply chain and feature many of pharma’s biggest names and breakthrough companies.

  5. Melbourne-Developed Drug Delivery Platform Delivers 'Impressive' Results In International Bowel And Ovarian Cancer Trial 9/12/2023

    A ground-breaking nanoscale drug delivery technology used to enhance the safety and performance of cancer drugs has been credited with “impressive” results in two of Australia’s most common cancers – colorectal (bowel) and ovarian cancer.

  6. Otsuka Collaborates With ShapeTX To Develop Novel AAV Gene Therapies For Ocular Diseases 9/7/2023

    Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types.

  7. Sirio Launches Pharma Targeted Softgels At CPHI Barcelona 8/25/2023

    Sirio Europe (SIRIO) – the leading global nutraceuticals contract development and manufacturing organization (CDMO) – will launch two new softgels targeted at customers who look to innovate in the consumer health space at CPHI Barcelona

  8. Qosina Adds OneShot™ Single-Use Filling Needles From Overlook Industries To Its Bioprocess Components Portfolio 8/24/2023

    Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce OneShot™ single-use filling needles from Overlook Industries, a manufacturer of single-use filling needles and molded fluid path assemblies for pharma and biopharma fill-finish machinery.

  9. Honeywell And Recipharm To Speed Development Of Inhalers With A Near-Zero Global Warming Potential Propellant 8/17/2023

    Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.

  10. NIH And Exothera Collaborate To Produce GMP Intranasal Vaccine Against SARS-CoV-2 For Clinical Phase I/II Trial In Africa And US 8/16/2023

    The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, oncolytic viruses, and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part of the Cooperative Research and Development Agreement, CRADA, they will be joined by researchers from Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine with special expertise in mucosal immunity and the design and conduct of early phase clinical trials.